Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Invest New Drugs. 2015 Mar 31;33(3):621–631. doi: 10.1007/s10637-015-0226-6

Figure 2B.

Figure 2B

Kaplan–Meier curves comparing overall survival between anti-EGFR pretreated patients (broken red line) and with no pretreatment (solid black line). Patients with anti-EGFR pretreatment tended toward a longer survival (median 9.4 [IQR 7.6 to 12.5] months vs. 4.8 [IQR 4.3 - 5.7] months respectively, log-rank p=0.187).